CD8A and neoplasm: It is demonstrated that BCa patients with heavy CD8 T cell infiltration benefit more immune-checkpoint inhibitor therapies due to the higher accessibility of neoantigens, tumor-specific antigens encoded by mutated genes [38, 40].